Apoptosis in asymptomatic HIV-1 seropositives immunized with HIV-1 env glycoprotein (gp160): Effects of administration of Zidovudine in vivo and interleukin-2 in vitro

被引:3
|
作者
Pierdominici, M
Mollicone, B
Ricci, G
Oliva, A
D'Offizi, G
Giovannetti, A
Aiuti, F
Pandolfi, F
机构
[1] Univ Roma La Sapienza, Chair Clin Immunol & Allergy, I-00185 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Chair Semeiot Med, I-00168 Rome, Italy
关键词
D O I
10.1016/S0264-410X(97)00251-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this paper we report the effects of VaxSyn(R) (Protein Sciences Corp.) immunization on spontaneous apoptosis ocurring in vitro after culture of PBMC in medium alone in 30 HIV-seropositive patients enrolled in a double-blind clinical trial that included three groups: treatment with VaxSyn, AZT and VaxSyn, and AZT. Our data show no significant modifications in the levels of apoptosis observed in the three groups over the long-term follow-up (up to 720 days). This was not associated with any significant modifications in other clinical or immunological features. However, analysis of apoptosis performed shortly after the first immunization (at days 3 and 7) showed a significant reduction in the rate of apoptosis in patients receiving AZT or AZT and VaxSyn, as compared with patients receiving VaxSyn alone (30.42 +/- 2.52 SE at day 0 and 23.74 +/- 1.84 at day 3; p = 0.039). Our data also indicate that addition of IL-2 in vitro had a significant inhibitory effect on mortality in all the randomization groups, especially in those receiving AZT (alone or in combination with VaxSyn). (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:715 / 721
页数:7
相关论文
共 50 条
  • [1] COMPLEMENT ACTIVATION BY GP160 GLYCOPROTEIN OF HIV-1
    THIEBLEMONT, N
    HAEFFNERCAVAILLON, N
    WEISS, L
    MAILLET, F
    KAZATCHKINE, MD
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 (03) : 229 - 233
  • [2] Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine
    Lambert, JS
    Viscidi, R
    Walker, MC
    Clayman, B
    Winget, M
    Wolff, M
    Schwartz, DH
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (03) : 302 - 308
  • [3] Immunisation with gp160 in HIV-1 infection
    Flala, C
    Stewart, GT
    LANCET, 1999, 354 (9182): : 948 - 948
  • [4] SYNTHESIS AND PROCESSING OF HIV-1 GP160 IN CELLS WITH DEFECTIVE HIV-1 GENOMES
    KALYANARAMAN, VS
    RODRIGUEZ, V
    GALLO, RC
    SARNGADHARAN, MG
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1991, 7 (02) : 197 - 197
  • [5] Expression of HIV-1 env Glycoprotein gp120 and gp160 in Vaccinia Virus System and Their Antigenicity Analysis
    陈元鼎
    Rodolfo Garcia
    Sergio Tisminetzky
    郭仁
    Francisco E.Baralle
    Chinese Medical Sciences Journal, 1997, (02) : 132 - 132
  • [6] Structural investigation of the HIV-1 envelope glycoprotein gp160 cleavage site
    Oliva, R
    Leone, M
    Falcigno, L
    D'Auria, G
    Dettin, M
    Scarinci, C
    Di Bello, C
    Paolillo, L
    CHEMISTRY-A EUROPEAN JOURNAL, 2002, 8 (06) : 1467 - 1473
  • [7] The extracellular processing of HIV-1 envelope glycoprotein gp160 by human plasmin
    Okumura, Y
    Yano, M
    Murakami, M
    Mori, S
    Towatari, T
    Kido, H
    FEBS LETTERS, 1999, 442 (01) : 39 - 42
  • [8] Immunisation with gp160 in HIV-1 infection -: Reply
    Sandstöm, EG
    Wahren, B
    LANCET, 1999, 354 (9182): : 949 - 949
  • [9] Illustrating the correlations between protein dynamics and glycan shielding of HIV-1 Env gp160
    Suresh, Raghavendran
    Mani, Natesan
    Chakraborty, Srirupa
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 189A - 189A
  • [10] HIV-1 gp160 induces alterations in ion transport
    Comardelle, AM
    Gatti, PJ
    Plymale, DR
    Choi, BK
    Norris, CH
    Fermin, CD
    Beary, TP
    Tencza, SB
    Montelaro, RC
    Garry, RF
    FASEB JOURNAL, 1997, 11 (03): : 3091 - 3091